Myelodysplastic Syndromes (MDS)
Medicine Central™ is a quick-consult mobile and web resource that includes diagnosis, treatment, medications, and follow-up information on over 700 diseases and disorders, providing fast answers—anytime, anywhere. Explore these free sample topics:
-- The first section of this topic is shown below --
- Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal stem cell disorders characterized by peripheral blood cytopenias: anemia, thrombocytopenia, and/or neutropenia.
- Dysplasia refers to an abnormality of development or differentiation in specific cell lines. In MDS, these changes take place in the bone marrow, and confer a tendency for leukemic transformation.
The incidence in the United States is approximately 3 to 4 cases per 100,000 population per year, expanding to 30 cases per 100,000 population per year, for patients age >70 years.
In 2012, >60,000 people with MDS resided in the country.
Etiology and Pathophysiology
- MDS is clinically characterized by peripheral cytopenias, consequence of ineffective marrow hematopoiesis (premature cell death).
- Nongenetic mechanisms encompass apoptosis, pyroptosis, deregulated immunity, and inflammatory cytokine amplification (see “Genetics” for genetic mechanisms) (1,2).
- Low-risk MDS (LR-MDS) are characterized by deregulated immunity and apoptosis, whereas high-risk MDS (HR-MDS) are characterized by clonal expansion and transformation to acute myelogenous leukemia (AML).
- A changing interplay of proapoptotic versus antiapoptotic signals is central in the progression of the disease.
- In LR-MDS, stem cell programmed death occurs by different mechanisms: apoptosis, pyroptosis, and potentially autophagy.
- Apoptosis: Tumor necrosis factor (TNF)-α, TNF-related apoptosis-inducing ligand (TRAIL), Fas ligand, and proapoptotic cytokines (TNF-α and IL-6) play a major role in stem cell apoptosis in LR-MDS.
- Pyroptosis: It is an inflammatory cell death different from apoptosis that is considered sterile in nature.
- Activation of nod-like receptors leads to formation of the inflammasome complex and caspase 1 activation that leads to pore formation in the plasma membrane of the cells; creates ionic gradients, water influx, cell swelling, and cell death (3)
- This potentially also explains the morphologic changes seen in MDS (macrocytosis, enlarged cells).
- Evolution to AML has been associated with upregulation of NFκB, enhanced activity of the Bcl-2 and the inhibitors of apoptosis protein (IAP) families.
- This is thought to be a mechanism of bypassing the apoptotic phenomenon in the bone marrow micro environment.
- Recurrent somatic mutations are observed in >90% of MDS patients.
- Mutated genes are involved in:
- Epigenetic regulation: TET2, EZH2, IDH1, IDH2, DNMT3A, ASXL1
- DNA repair: TP53
- Transcriptional regulation: BCOR, ETV6, RUNX1
- RNA splicing: U2AF35, ZRSR2, SF3B1, SRSF2
- Cohesin complex: STAG2
- Signal transduction: JAK2, CBL, NRAS
- Mutations in the epigenetic modifiers: The concept is that any gain of function mutations in the DNA methyltransferases (DNMT3A and DNMT3B) leads to hypermethylation (a gene silencing mechanism that contributes to clonal evolution).
- It is unclear how these different molecular and genetic mechanisms translate into the same phenotypic manifestation of myelodysplasia and cytopenias.
- Age: increased risk in patients >60 years old
- Tobacco use
- Chronic exposure to chemicals: benzene, pesticides, insecticides, and petroleum
- Prior chemotherapy or radiation therapy
- Inherited disorders: Fanconi anemia, Shwachman-Diamond syndromes, severe congenital neutropenia, and familial platelet disorder
Avoiding known cancer-causing industrial chemicals, such as benzene, and also tobacco, might lower the risk of developing MDS.
Commonly Associated Conditions
Myeloproliferative disorders and paroxysmal nocturnal hemoglobinuria